Charles Lu

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Suspected spinal cord compression in cancer patients: a multidisciplinary risk assessment
    Charles Lu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    J Support Oncol 3:305-12. 2005
  2. ncbi request reprint Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer
    Xin Lin
    Departments of Epidemiology and Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1155 Pressler Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 12:5720-5. 2006
  3. doi request reprint Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia
    Linda S Elting
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd Unit 447, Houston, TX 77030, USA
    J Clin Oncol 26:606-11. 2008
  4. pmc Human papillomavirus and survival of patients with oropharyngeal cancer
    K Kian Ang
    University of Texas M D Anderson Cancer Center, Houston, USA
    N Engl J Med 363:24-35. 2010
  5. pmc Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans
    Charles Lu
    The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e34833. 2012
  6. ncbi request reprint Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma
    Charles Lu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 106:441-7. 2006
  7. pmc Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial
    Charles Lu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030 4009, USA
    J Natl Cancer Inst 102:859-65. 2010
  8. ncbi request reprint Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers
    Charles Lu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 22:4575-83. 2004
  9. pmc Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy
    Xifeng Wu
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1340, Houston, TX 77030, USA
    J Natl Cancer Inst 103:817-25. 2011
  10. pmc Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer
    Michelle A T Hildebrandt
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 5:e12402. 2010

Detail Information

Publications46

  1. ncbi request reprint Suspected spinal cord compression in cancer patients: a multidisciplinary risk assessment
    Charles Lu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    J Support Oncol 3:305-12. 2005
    ..These predictors may help clinicians to assess risk in this patient population...
  2. ncbi request reprint Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer
    Xin Lin
    Departments of Epidemiology and Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1155 Pressler Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 12:5720-5. 2006
    ..We hypothesized that the expression of these genes would have significant predictive value for cancer development and prognosis...
  3. doi request reprint Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia
    Linda S Elting
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd Unit 447, Houston, TX 77030, USA
    J Clin Oncol 26:606-11. 2008
    ..We retrospectively compared the outcomes and costs of outpatient and inpatient management of low-risk outpatients who presented to an emergency department with febrile neutropenia (FN)...
  4. pmc Human papillomavirus and survival of patients with oropharyngeal cancer
    K Kian Ang
    University of Texas M D Anderson Cancer Center, Houston, USA
    N Engl J Med 363:24-35. 2010
    ..Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) are associated with favorable survival, but the independent prognostic significance of tumor HPV status remains unknown...
  5. pmc Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans
    Charles Lu
    The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e34833. 2012
    ..No drug strategies currently exist targeting loss-of-function genetic abnormalities. We report the first in-human systemic gene therapy clinical trial of tumor suppressor gene TUSC2...
  6. ncbi request reprint Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma
    Charles Lu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 106:441-7. 2006
    ....
  7. pmc Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial
    Charles Lu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030 4009, USA
    J Natl Cancer Inst 102:859-65. 2010
    ..CONCLUSIONS The addition of AE-941 to chemoradiotherapy did not improve overall survival in patients with unresectable stage III NSCLC. This study does not support the use of shark cartilage-derived products as therapy for lung cancer...
  8. ncbi request reprint Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers
    Charles Lu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 22:4575-83. 2004
    ....
  9. pmc Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy
    Xifeng Wu
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1340, Houston, TX 77030, USA
    J Natl Cancer Inst 103:817-25. 2011
    ..Interindividual variation in genetic background may influence the response to chemotherapy and overall survival for patients with advanced-stage non-small cell lung cancer (NSCLC)...
  10. pmc Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer
    Michelle A T Hildebrandt
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 5:e12402. 2010
    ..These results suggest that genetic variations among inflammation pathway genes may modulate the development of radiation-induced toxicity and, ultimately, help in identifying patients who are at an increased likelihood for such events...
  11. pmc Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy
    Xifeng Wu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Pharmacogenet Genomics 18:955-65. 2008
    ..Therefore, we applied a pathway-based approach to evaluate the cumulative effect of multiple polymorphisms on clinical outcome of patients with non-small cell lung cancer...
  12. doi request reprint Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer
    Samir Sejpal
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:3004-13. 2011
    ..We hypothesized that proton beam therapy for most patients with NSCLC could permit higher tumor doses with less normal-tissue toxicity than photon RT delivered as 3-dimensional conformal RT (3D-CRT) or intensity-modulated RT (IMRT)...
  13. ncbi request reprint High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy
    Joe Y Chang
    Department of Radiation Oncology, Epidemiology, and Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:2894-8. 2005
    ....
  14. pmc High symptom burden prior to radiation therapy for head and neck cancer: a patient-reported outcomes study
    G Brandon Gunn
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Head Neck 35:1490-8. 2013
    ..As a first step toward developing effective strategies to control symptoms associated with head and neck cancer (HNC) and its treatment, we sought to describe the pattern of symptoms experienced before radiation therapy...
  15. pmc Levels of symptom burden during chemotherapy for advanced lung cancer: differences between public hospitals and a tertiary cancer center
    Charles S Cleeland
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:2859-65. 2011
    ..We compared risk factors for high disease- and treatment-related symptom burden over 15 weeks of therapy in medically underserved patients with advanced non-small-cell lung cancer and in patients treated at a tertiary cancer center...
  16. pmc PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy
    Xia Pu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Lung Cancer 71:82-8. 2011
    ..With further validation, our findings may provide additional biomarkers for customized treatment of platinum-based chemotherapy for NSCLC...
  17. ncbi request reprint Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial
    Ritsuko Komaki
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 58:1369-77. 2004
    ..To determine the ability of amifostine to reduce the severity and/or incidence of the acute toxicities of concurrent chemotherapy and radiotherapy (RT) for non-small-cell lung cancer...
  18. ncbi request reprint Genetic variants in cell cycle control pathway confer susceptibility to lung cancer
    Wei Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:5974-81. 2007
    ..To test the hypothesis that common sequence variants of cell cycle control genes may affect lung cancer predisposition...
  19. pmc Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer
    Jingyao Dai
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e21120. 2011
    ..To our knowledge, this is the first study to reveal the importance of RGS gene family in the survival of late-stage NSCLC patients...
  20. pmc ATM sequence variants associate with susceptibility to non-small cell lung cancer
    Hushan Yang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX
    Int J Cancer 121:2254-9. 2007
    ....
  21. pmc Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer
    Moubin Lin
    Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 32:1050-6. 2011
    ..These results suggest that genetic variations in the TGF-β pathway are potential predictors of overall survival in NSCLC patients treated with platinum-based chemotherapy with or without radiation...
  22. ncbi request reprint Telomere length in peripheral blood leukocytes and lung cancer risk: a large case-control study in Caucasians
    Beatriz Sánchez-Espiridión
    Authors Affiliations Departments of Epidemiology, Radiation Oncology, Thoracic Head and Neck Medical Oncology, and Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer Res 74:2476-86. 2014
    ..In contrast, long telomeres were protective against SCC, particularly in male patients. Our results extend the concept that telomere length affects risk of lung cancer in a manner that differs with histologic subtype...
  23. pmc Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Cancer 117:4707-13. 2011
    ..They report early results of a phase 2 study of high-dose proton therapy and concurrent chemotherapy in terms of toxicity, failure patterns, and survival...
  24. ncbi request reprint Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer
    Jian Gu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 12:7329-38. 2006
    ..The aim of this study was to investigate the prognostic value of hypermethylation of tumor suppressor genes in patients with non-small cell lung cancer (NSCLC)...
  25. pmc Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer
    Jikai Yin
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX 77030, USA
    Carcinogenesis 32:1867-71. 2011
    ..These results suggest that genetic variations in cell cycle pathway genes may affect the survival of patients with stages III-IV NSCLC individually and jointly...
  26. ncbi request reprint Deficient G2-M and S checkpoints are associated with increased lung cancer risk: a case-control analysis
    Jinliang Xing
    Department of Epidemiology, Unit 1340, The University of Texas M D Anderson Cancer Center, 1155 Pressler Boulevard, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 16:1517-22. 2007
    ..Additionally, cell accumulation indices at both G2-M and S phases were not associated with clinical stages. We conclude that attenuated functions of G2-M and S cell cycle checkpoints might be susceptibility markers for lung cancer...
  27. doi request reprint Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
    Hai T Tran
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030, USA
    Invest New Drugs 29:499-505. 2011
    ..To assess the pharmacokinetics and evaluate potential drug-drug interactions between erlotinib, paclitaxel and carboplatin...
  28. pmc Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk
    Jie Lin
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 33:1699-706. 2012
    ..Future studies are needed to identify the causal SNPs and elucidate the underlying molecular mechanisms...
  29. ncbi request reprint A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer
    Charles Lu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:2085-91. 2003
    ..In an effort to integrate paclitaxel and topotecan into the treatment of limited disease (LD) SCLC, we conducted a Phase I study of these agents administered as initial induction therapy...
  30. doi request reprint Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience
    Zhi Qin Jiang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 83:332-9. 2012
    ..In 2007, we published our initial experience in treating inoperable non-small-cell lung cancer (NSCLC) with intensity-modulated radiation therapy (IMRT). The current report is an update of that experience with long-term follow-up...
  31. ncbi request reprint Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors
    Hai T Tran
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 54:308-14. 2004
    ..The present study was designed to determine the toxicity and pharmacokinetics of carboplatin in combination with TNP-470 in comparison with the doublet regimen of paclitaxel and carboplatin in patients with solid tumors...
  32. pmc Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory
    Tito R Mendoza
    Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, Texas 77030, USA
    Oncologist 16:217-27. 2011
    ....
  33. pmc Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers
    Xifeng Wu
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 73:4028-38. 2013
    ..These findings identify several novel, candidate prognostic markers for NSCLC in never smokers, with eQTL analysis suggesting a potential biologic mechanism for a subset of these observed associations...
  34. ncbi request reprint Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
    George R Blumenschein
    Department of Thoracic and Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Invest New Drugs 26:81-7. 2008
    ..Oral vorinostat 400 mg qd was generally well tolerated but did not demonstrate efficacy as defined by tumor response in this small group of heavily pre-treated patients...
  35. ncbi request reprint Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: A prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 120:1975-84. 2014
    ..The goals were to understand the onset and trajectory of specific symptoms and their severity, identify clusters, and facilitate symptom interventions and clinical trial design...
  36. ncbi request reprint Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma
    Charles Lu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 23:3495-501. 2005
    ..To determine pathologic response rates to liposome-entrapped cis-bisneodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) (L-NDDP) administered intrapleurally in patients with malignant pleural mesothelioma...
  37. ncbi request reprint Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer
    Jie Wang
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:6119-25. 2004
    ....
  38. ncbi request reprint Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk
    Matthew B Schabath
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Epidemiol 161:412-22. 2005
    ..19, 0.66) protective genotypes as compared with none (OR = 0.69, 95% CI: 0.30, 1.59). The biologic role of respiratory disease in lung cancer is unclear. Further study may yield new insights for identification of susceptible subgroups...
  39. pmc Initial medical attention on patients with early-stage non-small cell lung cancer
    Xing Chen
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e32644. 2012
    ..Understanding the reasons that caused initial detection of these patients is important for early diagnosis. However, these reasons are not well studied...
  40. ncbi request reprint The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 95:340-53. 2002
    ..The authors conducted a formal Phase II trial to evaluate the efficacy of this combination in both untreated and previously treated patients with Stage IIIB (with pleural effusion) or Stage IV NSCLC...
  41. ncbi request reprint Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians
    Jian Gu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Mutat Res 581:97-104. 2005
    ..02). Our data suggest that having a NAT2 slow acetylator genotype is a significant risk factor for BC, particularly in smokers and older individuals...
  42. ncbi request reprint Pharmacogenetics in esophageal cancer
    Xifeng Wu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Semin Oncol 32:S87-9. 2005
    ..This emergent area of biomedicine could lead to substantially improved clinical outcomes for patients with adenocarcinoma or squamous cell carcinoma of the esophagus...
  43. pmc Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer
    Xin Shelley Wang
    Department of Symptom Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:137-45. 2010
    ..However, translating patient-reported outcomes into useful prognostic information for individual patients has been problematic...
  44. ncbi request reprint Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors
    Fadlo R Khuri
    Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    Clin Cancer Res 10:2968-76. 2004
    ....
  45. ncbi request reprint Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians
    Jian Gu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center Houston, TX 77030, USA
    Carcinogenesis 28:350-5. 2007
    ..45% of controls) exhibited a reduced lung cancer risk (OR=0.78, 95% CI=0.63-0.97). This is the first epidemiological study to report significant associations between STK15 polymorphisms and lung cancer risk...
  46. ncbi request reprint Genome sequence of Theileria parva, a bovine pathogen that transforms lymphocytes
    Malcolm J Gardner
    Institute for Genomic Research TIGR, 9712 Medical Center Drive, Rockville, MD 20850, USA
    Science 309:134-7. 2005
    ..Several biosynthetic pathways are incomplete or absent, suggesting substantial metabolic dependence on the host cell. One protein family that may generate parasite antigenic diversity is not telomere-associated...